Filed with ASX · · 3 pages · English
Island Pharmaceuticals Ltd has announced the commencement of pre-trial surgeries for non-human primates as part of a study on Galidesivir targeting Marburg Virus Disease. These surgical preparations are crucial for facilitating drug delivery and monitoring during the upcoming dosing phase, which is expected to begin shortly after recovery. The study aims to identify the optimal dosing regimen for Galidesivir to support future efficacy studies under the FDA's Animal Rule pathway. This announcement marks a significant operational milestone for the company as it progresses towards its planned dosing schedule.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
4 November 2026 ASX Announcement Pre-trial surgeries commenced for NHP cohorts in USAMRIID Marburg study ahead of dosing in December • USAMRIID commences scheduled surgical preparations for 22 non-human primates (NHPs) ahead of Galidesivir Marburg dose optimisation study • Procedures form part...
Island Pharmaceuticals Ltd on 6ix
